-
公开(公告)号：US09750761B2
公开(公告)日：2017-09-05
申请号：US14718933
申请日：2015-05-21
IPC分类号： A01N35/00 , A61K31/11 , A61K31/713 , A61K31/404 , A61K45/06 , A61K31/12 , C12N15/113
CPC分类号： A61K31/713 , A61K31/12 , A61K31/404 , A61K45/06 , C12N15/1137 , C12N2310/14 , C12N2320/31 , C12Y101/01027 , C12Y101/01028 , A61K2300/00
摘要： One aspect of the disclosure relates to methods of treating a fibrotic condition in an individual. The methods include administering to an individual having a fibrotic condition an effective amount of a lactic dehydrogenase (LDH) inhibitor, wherein the fibrotic condition involves an internal organ or tissue, or ocular tissue, and said administering is effective to treat the fibrotic condition. Methods of administration and pharmaceutical compositions and systems for practicing such methods are also disclosed.
-
2.发明申请公开(公告)号：US20150335674A1
公开(公告)日：2015-11-26
申请号：US14718933
申请日：2015-05-21
IPC分类号： A61K31/713 , C12N15/113 , A61K31/12 , A61K31/404 , A61K45/06
CPC分类号： A61K31/713 , A61K31/12 , A61K31/404 , A61K45/06 , C12N15/1137 , C12N2310/14 , C12N2320/31 , C12Y101/01027 , C12Y101/01028 , A61K2300/00
摘要： One aspect of the disclosure relates to methods of treating a fibrotic condition in an individual. The methods include administering to an individual having a fibrotic condition an effective amount of a lactic dehydrogenase (LDH) inhibitor, wherein the fibrotic condition involves an internal organ or tissue, or ocular tissue, and said administering is effective to treat the fibrotic condition. Methods of administration and pharmaceutical compositions and systems for practicing such methods are also disclosed.
摘要翻译： 本公开的一个方面涉及治疗个体中的纤维化病症的方法。 所述方法包括向具有纤维化病症的个体施用有效量的乳酸脱氢酶（LDH）抑制剂，其中所述纤维化病症涉及内部器官或组织或眼组织，并且所述施用对于治疗所述纤维化病症是有效的。 还公开了施用方法和用于实施这些方法的药物组合物和系统。
-
3.发明授权Methods of treating or preventing an infectious disease using an immunogenic conjugate of a gram-negative bacterial autoinducer molecule 失效使用革兰氏阴性细菌自身诱导剂分子的免疫原性缀合物治疗或预防感染性疾病的方法公开(公告)号：US07384639B2
公开(公告)日：2008-06-10
申请号：US11220224
申请日：2005-09-06
IPC分类号： A61K39/385 , A61K39/02 , A61K39/108 , A61K39/106 , A61K39/00
CPC分类号： C07D207/273 , A61K39/385 , A61K2039/505 , A61K2039/6081 , C07D263/26 , C07D307/33 , C07D333/36 , C07K16/1203 , C07K16/1214 , G01N33/56911 , Y10S435/975 , Y10S436/80 , Y10S436/804 , Y10S530/806 , Y10S530/808
摘要： The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.
摘要翻译： 本发明涉及包含与革兰氏阴性细菌的自身诱导剂偶联的载体分子的免疫原性缀合物。当与药学上可接受的载体组合时，免疫原性缀合物形成用于哺乳动物以防止革兰氏阴性细菌感染的合适疫苗。免疫原性缀合物 也用于提高和随后分离能够识别和结合自动诱导剂的抗体或其结合部分。 抗体或其结合部分用于治疗感染的方法，抑制自身诱导剂活性的方法，以及用于检测流体或组织样品中自身诱导剂或自身诱导剂拮抗剂的存在的诊断测定。
-
公开(公告)号：US06958219B2
公开(公告)日：2005-10-25
申请号：US10772599
申请日：2004-02-05
IPC分类号： A61K39/385 , C07D207/26 , C07D207/273 , C07D263/26 , C07D307/33 , C07D333/36 , C07K16/12 , G01N33/53 , G01N33/542 , G01N33/559 , G01N33/569
CPC分类号： C07D207/273 , A61K39/385 , A61K2039/505 , A61K2039/6081 , C07D263/26 , C07D307/33 , C07D333/36 , C07K16/1203 , C07K16/1214 , G01N33/56911 , Y10S435/975 , Y10S436/80 , Y10S436/804 , Y10S530/806 , Y10S530/808
摘要： The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria. The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.
摘要翻译： 本发明涉及包含与革兰氏阴性细菌的自动诱导剂偶联的载体分子的免疫原性缀合物。 当与药学上可接受的载体组合时，免疫原性缀合物形成用于哺乳动物的合适的疫苗，以防止革兰氏阴性菌感染。 免疫原性缀合物也用于引发和随后分离能够识别和结合自动诱导剂的抗体或其结合部分。 抗体或其结合部分用于治疗感染的方法，抑制自身诱导剂活性的方法，以及用于检测流体或组织样品中自身诱导剂或自身诱导剂拮抗剂的存在的诊断测定。
-
公开(公告)号：US20170281326A1
公开(公告)日：2017-10-05
申请号：US15451078
申请日：2017-03-06
CPC分类号： A61F2/0063 , A61F2/0077 , A61F13/00008 , A61F13/00017 , A61F13/00029 , A61F13/00034 , A61F13/00042 , A61F13/00063 , A61F2002/0068 , A61F2002/009 , A61F2013/00157 , A61F2013/00238 , A61F2013/00251 , A61F2250/0067 , A61K31/35 , A61L15/18 , A61L15/26 , A61L15/425 , A61L15/44 , A61L26/0019 , A61L26/0066 , A61L26/0085 , A61L27/18 , A61L27/60 , A61L2300/30 , A61L2300/406 , C08L83/04 , D04B1/104 , D04B1/16 , D10B2403/0112 , D10B2509/022 , C08L77/00
摘要： An improved abdominal hernia repair system is presented comprised of a silicone layer backed up with a knitted or woven polypropylene fabric layer, the silicone layer possessing a regular pattern of slits that permit equilibration of fluid pressure across the device. A variety of therapeutic substances can be applied to the hernia repair device to promote healing, including aloe and other medicinal preparations. A layer of water soluble or water insoluble anti-scar compound is also present, the preferred compound being Salinomycin.An improved inguinal hernia repair system is presented that is identical to the above except it does not contain the hydrophobic silicone component.
-
公开(公告)号：US09694050B2
公开(公告)日：2017-07-04
申请号：US14437378
申请日：2013-10-21
IPC分类号： A61K38/16 , A61K38/00 , A61K38/17 , C12N15/113 , A61K9/00 , C07K14/705
CPC分类号： A61K38/177 , A61K9/0014 , A61K9/0048 , A61K38/1774 , C07K14/70503 , C12N15/1138 , C12N2310/113 , C12N2310/141
摘要： The present invention relates to methods of treating a condition involving excessive adipogenesis. This method relates to selecting a subject having a condition involving excessive adipogenesis and administering to the selected subject a composition comprising a Thy1 protein or polypeptide fragment thereof, or an agent that enhances Thy1 expression, under conditions effective to treat the condition. The present invention also relates to isolated nucleic acid molecules encoding a Thy1 protein or the fragment thereof and pharmaceutical formulations including such a protein or fragment thereof or an agent that enhances Thy1 expression and a pharmaceutically acceptable carrier. The present invention also relates to methods of inhibiting adipogenesis and/or decreasing adipocyte size, as well as methods of screening a candidate compound for its ability to influence adipogenesis.
-
7.发明申请THY1 (CD90) AS A NOVEL THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION 有权THY1（CD90）作为控制ADIPOSE组织积累的新疗法公开(公告)号：US20150283205A1
公开(公告)日：2015-10-08
申请号：US14437378
申请日：2013-10-21
IPC分类号： A61K38/17 , C12N15/113 , A61K9/00
CPC分类号： A61K38/177 , A61K9/0014 , A61K9/0048 , A61K38/1774 , C07K14/70503 , C12N15/1138 , C12N2310/113 , C12N2310/141
摘要： The present invention relates to methods of treating a condition involving excessive adipogenesis. This method relates to selecting a subject having a condition involving excessive adipogenesis and administering to the selected subject a composition comprising a Thy1 protein or polypeptide fragment thereof, or an agent that enhances Thy1 expression, under conditions effective to treat the condition. The present invention also relates to isolated nucleic acid molecules encoding a Thy1 protein or the fragment thereof and pharmaceutical formulations including such a protein or fragment thereof or an agent that enhances Thy1 expression and a pharmaceutically acceptable carrier. The present invention also relates to methods of inhibiting adipogenesis and/or decreasing adipocyte size, as well as methods of screening a candidate compound for its ability to influence adipogenesis.
摘要翻译： 本发明涉及治疗涉及过量脂肪生成的病症的方法。 该方法涉及选择具有过度脂肪形成的病症的受试者，并且在有效治疗病症的条件下，向选定受试者施用包含Thy1蛋白或其多肽片段或增强Thy1表达的药物。 本发明还涉及编码Thy1蛋白或其片段的分离的核酸分子和包含这种蛋白质或其片段的药物制剂或增强Thy1表达的药剂和药学上可接受的载体。 本发明还涉及抑制脂肪形成和/或减少脂肪细胞大小的方法，以及筛选候选化合物以影响脂肪形成的能力的方法。
-
公开(公告)号：US20110300129A1
公开(公告)日：2011-12-08
申请号：US13139220
申请日：2009-12-14
IPC分类号： A61K39/395 , A61P39/00 , C12N5/078 , A61P31/04 , A61K39/02 , A61P37/04 , A61P31/12 , A61P33/00 , A61K45/06 , A61K39/12
CPC分类号： A61K31/195 , A61K31/20 , A61K39/12 , A61K39/39 , A61K45/06 , A61K2039/5258 , A61K2039/55561 , C12N5/0635 , C12N2501/056 , C12N2501/385 , C12N2710/20023 , C12N2710/20034
摘要： Pharmaceutical compositions of the invention include an antigen or a nucleic acid molecule encoding the antigen; one or both of a PPAR ligand and an RxR ligand; and a pharmaceutically suitable carrier. The pharmaceutical composition can optionally include a mitogen or other additives. Also disclosed are methods of inducing B cell differentiation and promoting an immune response against an antigen.
摘要翻译： 本发明的药物组合物包括编码抗原的抗原或核酸分子; 一个或两个PPAR配体和RxR配体; 和药学上合适的载体。 药物组合物可任选地包括丝裂原或其它添加剂。 还公开了诱导B细胞分化并促进针对抗原的免疫应答的方法。
-
9.发明申请USE OF ELECTROPHILIC COMPOUNDS FOR INDUCING PLATELET PRODUCTION OR MAINTAINING PLATELET FUNCTION 有权电子化合物用于诱导电极生产或维持电极功能的用途公开(公告)号：US20110027223A1
公开(公告)日：2011-02-03
申请号：US12738949
申请日：2008-10-29
申请人： Richard P. Phipps , Jamie O'Brien
发明人： Richard P. Phipps , Jamie O'Brien
IPC分类号： A61K38/20 , A61K31/19 , A61K31/416 , A61K31/12 , A61K31/381 , A61K38/36 , A61K38/17 , A61K38/18 , A61P7/04
CPC分类号： A61K31/5575 , A61K31/19 , A61K31/215 , A61K31/277 , A61K31/557 , A61K31/56 , A61K45/06
摘要： The present invention is directed to a method of inducing platelet production that includes contacting a megakaryocyte with an electrophilic compound under conditions effective to induce platelet production by the contacting megakaryocyte. Methods of treating a patient for low platelet levels, increasing the circulating half-life of platelets, and improving the quality (activity) of platelets are also disclosed herein, which involve administering the electrophilic compound to a patient an effective amount to achieve the desired effect. Pharmaceutical compositions and therapeutic systems are also disclosed for carrying out these therapeutic treatments.
摘要翻译： 本发明涉及诱导血小板产生的方法，其包括在有效诱导接触的巨核细胞产生血小板的条件下使巨核细胞与亲电子化合物接触。 本文还公开了治疗患者低血小板水平，增加血小板的循环半衰期以及提高血小板质量（活性）的方法，其包括将亲电化合物给予有效量以达到所需效果 。 还公开了用于进行这些治疗处理的药物组合物和治疗系统。
-
公开(公告)号：US10285794B2
公开(公告)日：2019-05-14
申请号：US15451078
申请日：2017-03-06
IPC分类号： A61F2/00 , A61F13/00 , A61L26/00 , A61K31/35 , A61L27/18 , A61L27/60 , A61L15/18 , A61L15/26 , A61L15/42 , A61L15/44 , D04B1/10 , D04B1/16 , C08L83/04
摘要： An improved abdominal hernia repair system is presented comprised of a silicone layer backed up with a knitted or woven polypropylene fabric layer, the silicone layer possessing a regular pattern of slits that permit equilibration of fluid pressure across the device. A variety of therapeutic substances can be applied to the hernia repair device to promote healing, including aloe and other medicinal preparations. A layer of water soluble or water insoluble anti-scar compound is also present, the preferred compound being Salinomycin.An improved inguinal hernia repair system is presented that is identical to the above except it does not contain the hydrophobic silicone component.
-
-
-
-
-
-
-
-
-
搜索结果
18 条记录 (耗时 0.023 秒)
